Effects of long-term therapy with arotinolol on blood pressure and renal function in hypertensive patients with chronic renal failure.
The effects on blood pressure and renal function of long-term treatment with the alpha- and beta-blocker arotinolol at a dose of 20 mg/day were studied in 10 hypertensive patients with chronic renal failure. Patients received low-protein therapy in which the protein and phosphorus intakes were controlled at a certain level. The average duration of arotinolol treatment was 18.4 months. A significant decrease in blood pressure was seen after the second month of treatment, and this effect continued up to the 20th month. The progression rates of renal failure (creatinine clearance/month) before and after treatment were -0.377 +/- 0.344 and -0.164 +/- 0.172 ml/min/month, respectively. No side effects attributable to the drug were observed. These findings indicate that arotinolol has a stable antihypertensive effect and no adverse effects on renal function. Arotinolol appears to be a useful drug in the long-term treatment of hypertension in patients with chronic renal failure.
Shiigai
T
T
Toride Kyodo General Hospital, Ibaraki, Japan.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D003404:Creatinine / Q000097:blood / Q000652:urine; D004032:Diet; D004044:Dietary Proteins / Q000378:metabolism; D005260:Female; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000178:diet therapy / Q000503:physiopathology; D007677:Kidney Function Tests; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010758:Phosphorus / Q000652:urine; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D004044:Dietary Proteins; D011412:Propanolamines; D010758:Phosphorus; C024523:arotinolol; D003404:Creatinine